Brought to you by 
TearScience brings in $15mm through the sale of debt
08 May 2013
Executive Summary
TearScience Inc. (ophthalmic medical devices) has raised $15mm through the sale of debt to Oxford Finance and Silicon Valley Bank. The company will use the funds to commercialize its LipiFlow, a device that was recently cleared by the FDA to remove meibomian gland obstructions on the eyelid during a 12-minute in-office treatment for dry eye syndrome. TearScience has raised about $70mm from VC firms since it was established in 2005.
Deal Industry
- Medical Devices
-
Medical Devices
- Monitoring Equipment & Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TearScience brings in $15mm through the sale of debt
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice